Hengrui Medicine (01276.HK): SHR-4610 injection received drug clinical trial approval notice.

The Wisdom Finance APP reported that Hengrui Medicine (01276.HK) has announced that recently, its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the SHR-4610 injection, and will soon begin clinical trials.